pegamotecan: camptothecin-di-20-O-ester of PEG(40-kDa)Gly; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 11297617 |
| CHEMBL ID | 3989476 |
| MeSH ID | M0296520 |
| Synonym |
|---|
| pegamotecan (usan) |
| prothecan (tn) |
| D05385 |
| 581079-18-7 |
| ez-246 |
| pegamotecan |
| peg-camptothecin |
| DTXSID70206835 , |
| (s)-4-ethyl-3,14-dioxo-3,4,12,14-tetrahydro-1h-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl (2-(2-(2-(((s)-1-(((s)-4-ethyl-3,14-dioxo-3,4,12,14-tetrahydro-1h-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl)oxy)-1-oxopropan-2-yl)amino)-2-oxoethoxy)ethox |
| CHEMBL3989476 |
| AKOS040746212 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 2 (28.57%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (71.43%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||